Home›Trial›NCT06194799
🔬NCT06194799Phase 3ENROLLING BY INVITATION

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Study Summary

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

Conditions
Alzheimer's Disease Psychosis
Interventions / Drugs
ACP-204
View on ClinicalTrials.gov ↗
Sponsor
ACAD
ACADIA Pharmaceuticals
Neuroscience
D50/100
Study Details
Enrollment752 participants
Primary Completion—
Lead SponsorACADIA Pharmaceuticals Inc.
Data Retrieved2026-04-11 02:52:05.277003+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.